+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06530576

Phase 2 Study of Thalidomide Alone for Treating Symptomatic Large Granular Lymphocytic Leukemia in Adults

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-11-18

48

Participants Needed

1

Research Sites

55 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of thalidomide as a treatment for symptomatic Large Granular Lymphocytic Leukemia LGLL, a condition with no current standard first-line therapy. This study follows earlier findings where a combination of thalidomide, prednison, and methotrexate showed promising response rates in LGLL patients. The goal is to observe how effective thalidomide alone is in treating patients with symptomatic LGLL. Participants initially receive oral thalidomide at doses between 50 and 100 mg daily in 4-month cycles. After each cycle, researchers assess the treatment response. If thalidomide alone is effective, it continues for up to three courses. If partial remission is not achieved after the first cycle or complete remission is not reached after the second, methotrexate is added once weekly, continuing for up to three cycles. Treatment stops after a maximum of three cycles or if patients do not respond to the combination therapy. During the study, participants undergo regular evaluations to monitor response, safety, and remission status for up to five years. Researchers will measure overall response rate as the primary outcome and assess safety, complete remission rate, progression-free survival, overall survival, and remission duration as secondary outcomes. The study involves close monitoring of symptoms and laboratory tests to track the treatments impact over time.

CONDITIONS

Brief Title

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

Research Team

S

Shuhua Yi, Doctor

L

Lugui Qiu, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here